Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.com to Buy

StockNews.com cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research report released on Wednesday.

Several other analysts also recently weighed in on COLL. Piper Sandler reiterated an overweight rating and set a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Jefferies Financial Group restated a hold rating and issued a $37.00 price objective (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Needham & Company LLC restated a buy rating and issued a $40.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Finally, Truist Financial lifted their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a buy rating in a report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $39.00.

Collegium Pharmaceutical Stock Up 2.3 %

NASDAQ COLL opened at $37.78 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. The company has a fifty day moving average of $37.44 and a two-hundred day moving average of $31.62. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of 32.02 and a beta of 1.03. Collegium Pharmaceutical has a 52 week low of $20.83 and a 52 week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.20 by $0.25. The company had revenue of $149.75 million during the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. On average, analysts predict that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Large investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its holdings in Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after purchasing an additional 883,380 shares in the last quarter. SummerHaven Investment Management LLC raised its holdings in Collegium Pharmaceutical by 1.1% in the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after purchasing an additional 368 shares in the last quarter. Natixis Advisors L.P. raised its holdings in Collegium Pharmaceutical by 152.9% in the third quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock worth $1,215,000 after purchasing an additional 32,865 shares in the last quarter. Loomis Sayles & Co. L P raised its holdings in Collegium Pharmaceutical by 32.7% in the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock worth $6,116,000 after purchasing an additional 67,439 shares in the last quarter. Finally, Everence Capital Management Inc. bought a new position in Collegium Pharmaceutical in the fourth quarter worth about $302,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.